Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Madeleine (Maddy) Kane, Rachel Bervell, MD, MS, Angela Y. Zhang, MD, and Jennifer Tsai, MD, MEd
Algorithms use race as an epidemiological shorthand, but clinically influential historical, social, and cultural determinants of health are still sources of variability.
AMA J Ethics. 2022;24(8):E720-728. doi:
10.1001/amajethics.2022.720.
Professor Katie Watson joins Ethics Talk to consider key questions about clinical and legal risk management for clinicians trying keep patients safe and for patients with complex pregnancies trying to stay alive.
Dr Liam G. McCoy joins Ethics Talk to discuss his article, coauthored with Drs Zainab Doleeb, Jazleen Dada, and Catherine Allaire: “Underrecognition of Dysmenorrhea Is an Iatrogenic Harm.”
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.